E-Therapeutics Expands Diabetes Research Agreement with Novo Nordisk
01 August 2019 - 6:23PM
Dow Jones News
By Carlo Martuscelli
E-Therapeutics PLC (ETX.LN) said Thursday that it has signed an
expanded agreement with Novo Nordisk AS (NOVO-B.KO) to provide its
technology to aid in diabetes drug research.
The London-listed provider of digital technology for drug
discovery said that it will use its technology to analyze genetic
data in groups of patients with type 2 diabetes. This agreement
builds on a previously-signed collaboration with the Danish
pharmaceutical company in the space of drug discovery research.
The new deal extends the original contract by six months to June
2020, e-Therapeutics said.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
August 01, 2019 04:08 ET (08:08 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
